LAM561 not checked

Laminar Pharmaceuticals

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
2 active
4 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase. Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria,…”In the company’s words, NCT04250922 on ClinicalTrials.gov
Tested for
Primary Glioblastoma, Glioblastoma Multiforme, High-grade Glioma, Solid Tumor, Unspecified, Child
Main trialPhase 2/3
“The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy plus temozolomide (TMZ), followed by an adjuvant treatment of 6 month period of TMZ and then LAM561 or placebo in monotherapy.”In the company’s words, NCT04250922 on ClinicalTrials.gov

Other drugs for Primary Glioblastoma

All 125 drugs for Primary Glioblastoma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2/3Active, not recruiting 15 Jan 2026 LAM561 With RT and TMZ for Adults With Glioblastoma
Phase 1/2Recruiting Oct 2026 Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
Phase 1/2Completed Sep 2016 A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours
Phase 1Completed 1 Jul 2020 A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LAM561

Following is part of Solo: you see every change to LAM561 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in